Item# Name Size & Form Brand Price Actions
Item# 23052305 Oscillococcinum
by BoironBoiron $13.85 Wishlist
2 pack - $23.96
3 pack - $34.14
6 pack - $65.28
12 pack - $127.45

Supplement Facts

Active Ingredient Purpose

Anas barbariae hepatis et cordis extractum 200CK HPUS

To reduce the duration and severity of flu symptoms

The letters HPUS indicate that this ingredient is officially included in the Homeopathic Pharmacopeia of the United States

Inactive Ingredients: Sucrose, Lactose. (Contains 1g of sugar per dose)

Adults and children 2 years and older: Dissolve entire contents of one tube in the mouth every 6 hours, up to 3 times a day. Children under 2 years: Ask a doctor.

Warnings: Ask a doctor before use in children under 2 years of age. Stop use and ask a doctor if symptoms persist for more than 3 days or worsen. If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children.

Take Oscillo at the First Sign of Flu!

Oscillococcinum (o-sill-o-cox-see-num) is safe, natural and easy to take. Oscillo is used by millions of people and recommended by doctors around the world. Temporarily relieves symptoms of flu, such as fever, chills, body aches and pains.

Oscillococcinum is an anomaly in the homeopathic materia medica because it is one of the relatively few proprietary preparations. The name is registered by Boiron.

Scarcely known to the English-speaking world, it is one of the most widely used and popular homeopathic medicines in France. But even in France it is anomalous. It is the only homeopathic medicine authorized for routine production in France in a dilution above the 30c, and by the Korsakovian method.

All other homeopathic medicines in France are prepared by the Hahnemannian method, in potencies not exceeding 30c, although higher dilutions may be prepared on a named patient basis. The Korsakovian dilution method involves repeated incomplete emptying and refilling of a single piece of glassware, whereas the Hahnemannian demands fresh glassware for each dilution.

One medical review has only been able to say that the results look promising without giving a recommendation to use it.


The popular reputation of Oscillococcinum has now been vindicated by a large scale, double-blind, placebo controlled trial published in the British Journal of Clinical Pharmacology. 487 patients were recruited by 149 general practitioners (mostly non-homoeopaths) in the Rhone-Alpes region of France during the influenza epidemic of January-February 1987.

Entry criteria were: rectal temperature of 38oC or above, and at least two of the following symptoms: headache, stiffness, lumbar or articular pain and shivers. The first manifestations had to have occurred less than 24 hours before entry. Patients with immune deficiency, local infection, or who had been immunized against influenza were excluded.

Diagnosis was purely clinical, although the A H1N1 influenza virus was subsequently identified as being responsible for the epidemic. Patients were randomly assigned to active Oscillococcinum (237 patients) or identical placebo (241 patients), 5 doses at 12 hour intervals. Recovery was defined as temperature less than 37.5oC, with complete resolution of the 5 cardinal symptoms.

Results After 48 hours, 17% of the active treatment group had fully recovered, compared to 10% of the placebo group. This difference was statistically significant (p=0.03, X2 test). Further analysis showed that the effect of Oscillococcinum peaked at 36 hours, when 40% of recoveries were attributable to the treatment. It was most effective in younger patients - 68% of recoveries within 48 hours in the under-30’s were due to treatment; and when the illness was relatively mild - 52% of the recoveries from illnesses classified mild or moderate were due to treatment. Patients on active treatment used significantly less other treatment for pain and fever (50% v 41%, p=0.04), they also judged the active treatment more efficacious than placebo (61% v 49% p=0.02).

The Lancet commented favorably on the trial, remarking that the authors were restrained in their discussion, and describing the difference between placebo and active treatment as ‘respectable’. The Lancet’s report was ‘quadruple-blind’ mentioning only at the very end that the treatment was homoeopathic.


Ferley JP, Zmirou D, D’Adhemar D, Balducci F. A controlled evaluation of a homoeopathic preparation in influenza-like syndromes. Br J Clin Pharmac (1989)

Contact Us | Ordering Info | Privacy Policy | 105% Guarantee | Pay It Forward (5% Earned on Every Order) |

Twitter  Facebook  Blog

Paypal Visa Master Card Amex Discover Check Money Order

*Statements on this site have not been evaluated by the Food and Drug Administration. Products on this site are not intended to diagnose, treat, cure, or prevent any disease.

Prices are subject to change at anytime and without notice. The majority of the product information has been reprinted from the manufacturer.